Prediction of Ovarian Tumor Malignancy

Similar documents
Detection of Ovarian Cancer by Determination of Ca 125 in Different Patohistologycal Types of Tumor According to Age

Because ovarian cancer is usually diagnosed

American Journal of Oral Medicine and Radiology

3 Summary of clinical applications and limitations of measurements

Is It Time To Implement Ovarian Cancer Screening?

Adnexal Masses in Menopausal Women Surgery or Surveillance?

A new scoring model for characterization of adnexal masses based on two-dimensional gray-scale and colour Doppler sonographic features

Prospective evaluation of three different models for the pre-operative diagnosis of ovarian cancer

The role of ultrasound in detecting early ovarian carcinoma:the National Ovarian Cancer Early Detection Program

The natural history of adnexal cysts incidentally detected at. transvaginal ultrasound examination in postmenopausal women

Clinical, ultrasound parameters and tumor marker-based mathematical models and scoring systems in pre-surgical diagnosis of adnexal tumors

Adnexal Masses in Menopausal Women

IOTA and Models for Screening for Ovarian Cancer

The characterization of common ovarian cysts in premenopausal women

Metastatic Colonic Adenocarcinoma Simulating Primary Ovarian Neoplasm in Transvaginal Doppler Sonography

Ubol Saeng-Anan, Tawiwan Pantasri, Vithida Neeyalavira, Theera Tongsong*

Risk of Malignancy Index in the Preoperative Evaluation of Patients with Adnexal Masses among Women of Perimenopausal and Postmenopausal Age Group

RESEARCH COMMUNICATION

Multimodal approach to predict ovarian malignancy prior to laparoscopy

Role of Combining Colour Doppler and Grey Scale Ultrasound in Characterizing Adnexal Masses

A NEW QUANTITATIVE METHOD TO EVALUATE ADNEXAL TUMORS

Intratumoral Blood Flow Analysis in Ovarian Cancer:

Diagnosis of adnexal malignancies by using color Doppler energy imaging as a secondary test in persistent masses

ORIGINAL CONTRIBUTIONS

Three-dimensional Power Doppler Ultrasonography for Discriminating Benign from Malignant Ovarian Tumors:

Table E2. Studies from 1998 November 2008 That Focus on Performance of Imaging Modalities for Ovarian Lesion Detection and Characterization

RESEARCH ARTICLE. Hariyono Winarto*, Bismarck Joel Laihad, Laila Nuranna. Abstract. Introduction

Triage of Ovarian Masses. Andreas Obermair Brisbane

M. J. KUDLA* and J. L. ALCÁZAR ABSTRACT

Comparison of Lerner score, Doppler ultrasound examination, and their combination for discrimination between benign and malignant adnexal masses

REVIEW ARTICLE ABSTRACT

ISUOG Basic Training Typical Ultrasound Appearances of Common Pathologies in the Adnexae

SCREENING FOR OVARIAN CANCER DR MACİT ARVAS

A Practical Approach to Adnexal Masses

This policy is applicable to Commercial Products only. For BlueCHiP for Medicare, see Related Policy section.

Socio-Demographic Characteristics of Women with Endometrial Carcinoma

Does serum CA125 have clinical value for follow-up monitoring of postoperative patients with epithelial ovarian cancer? Results of a 12-year study

The diagnosis of endometriomas using colour Doppler energy imaging

CAN TV U/S REDUCE THE

Clinical correlation of ovarian mass with ultrasound findings and histopathology report

IN THE NAME OF GOD POV: CYSTIC OVARIAN LESION

A study of benign adnexal masses

DSJUOG ABSTRACT INTRODUCTION. Materials AND METHODS /jp-journals

بسم هللا الرحمن الرحيم. Prof soha Talaat

P. SLADKEVICIUS and L. VALENTIN ABSTRACT

Sonographic Prediction of Ovarian Malignancy in Adnexal Mass

Evaluation of the Ovarian Crescent Sign in the Preoperative Determination of the Nature of Adnexal Masses

CLINICAL PRESENTATION AND RADIOLOGY QUIZ QUESTION

Appendix cancer mimicking ovarian cancer

FDG-PET Findings in an Ovarian Endometrioma: A Case Report

Outcomes of sonography-based management of breast cysts

Gynecologic Cancers are many diseases. Gynecologic Cancers in the Age of Precision Medicine Advances in Internal Medicine. Speaker Disclosure:

TheFormationofaScoringSystemtoDiagnoseEndometriosis. The Formation of a Scoring System to Diagnose Endometriosis

Gynecologic Cancers are many diseases. Speaker Disclosure: Gynecologic Cancer Care in the Age of Precision Medicine. Controversies in Women s Health

Histological Pattern of Ovarian Neoplasma

FDG-PET value in deep endometriosis

Ovarian fibroma feigning carcinoma in a young female: a rare case presentation

Evaluation of serum level of CA-125 and HE4 in patients with an adnexal mass for the discrimination of benign from malignant cases

Focus on... Ovarian cancer. HE4 & ROMA score

The Adnexal Mass. Handout NCUS 3/18/2017 Suzanne Dixon, MD

Assessment of benefit of ultrasound monitoring of adnexal masses <10 cm on ovarian cancer early detection

Human epididymal protein 4 The role of HE4 in the management of patients presenting with pelvic mass Publication abstracts

RESEARCH ARTICLE. Role of a Risk of Malignancy Index in Clinical Approaches to Adnexal Masses

Ovarian fibromas/thecomas are uncommon

Short communication: A rare case of vaginal dermoid cyst: A case report and review of literature

Screening for Ovarian Cancer: Brief Evidence Update

Blood Flow in Functional Cysts and Benign Ovarian Neoplasms in Premenopausal Women

EDUCATIONAL COMMENTARY CA 125. Learning Outcomes

OVARIAN MASSES : MANAGEMENT CHALLENGE

Original Research Article

Ovarian Lesion Benign vs Malignant?

Summary CHAPTER 1. Introduction

Ask the Experts Obstetrics & Gynecology

Stage IA Ovarian Cancers

Utility of color Doppler indices of dominant follicular

Preoperative diagnosis of metastatic ovarian cancer is related to origin of primary tumor

Sonographic Diagnosis of Ovarian Masses

Adnexal Mass Management: Risk Stratification and Management Practice for Best Patient Outcomes

New York Science Journal 2017;10(3) Mahmoud Sayed El Edessy, Hesham Saleh mohammed, and Abd Alsttar Alwaziry

Histological pattern of ovarian tumors and their age distribution

Statistics as a Tool. A set of tools for collecting, organizing, presenting and analyzing numerical facts or observations.

Thrombopoietin: a novel candidate tumor marker for the diagnosis of ovarian cancer

Original Article Transvaginal sonographic characteristics of paraovarian borderline tumor

Evaluation of Adnexal Masses - Correlation of Clinical, Sonological and Histopathological Findings in Adnexal Masses

2/24/19. Ovarian pathology: IOTA ADNEXAL MASSES. Content. IOTA terms for description of an adnexal mass. IOTA terms for description of an adnexal mass

Adnexal Masses in Perimenopausal Women: How Effective is Color Flow Mapping and Pulse Doppler Waveform Studies in detecting Malignancy Preoperatively?

Significance of Ovarian Endometriosis on the Prognosis of Ovarian Clear Cell Carcinoma

A case of extremely rare ovarian tumor: Primary ovarian adenomyoma

As the proportion of the elderly in the

Shina Oranratanaphan, Tarinee Manchana*, Nakarin Sirisabya

Diagnostics guidance Published: 15 November 2017 nice.org.uk/guidance/dg31

LAPAROSCOPIC OVARIAN CYSTECTOMY: SELECTION OF PATIENTS AND CONSEQUENCES OF RUPTURE OF OVARIAN MALIGNANCY

Pre-operative Evaluation and Implications

The International Ovarian Tumour Analysis (IOTA) criteria

Diagnostic accuracy of ultrasonography with color doppler imaging techniques in adnexal masses and correlation with histopathological analysis

Protocol. Multimarker Serum Testing Related to Ovarian Cancer

Frequency and type of adnexal lesions in autopsy material from postmenopausal women: ultrasound study with histological correlation

Screening Postmenopausal Women for Ovarian Cancer

Is CA-125 the Leading Biomarker in Determining Early-Onset Ovarian Cancer Diagnosis in 2016?

CASE STUDY. Presented by: Jessica Pizzo. CFCC Sonography student Class of 2018

Transcription:

Coll. Antropol. 35 (2011) 3: 775 779 Original scientific paper Prediction of Ovarian Tumor Malignancy Hrvojka Solja~i} Vrane{ 1, Petar Klari} 1, Zdenko Sonicki 2, Vesna Gall 1, Marija Juki} 1 and Ante Vukovi} 1 1 University of Zagreb,»Sestre milosrdnice«university Hospital Center, Department of Gynecology and Obstetrics, Zagreb, Croatia 2 University of Zagreb,»Andrija [tampar«school of Public Health, Department for Medical Statistics, Epidemiology, and Medical Informatics, Zagreb, Croatia ABSTRACT Ovarian cancer is the leading cause of mortality among gynecological cancers. The aim of the study was to form the decision rules for distinguishing from ovary lesions. The research was conducted on 201 women with ovary tumor. Commonly used specific markers for ovarian cancer (biochemical marker Ca 125, ultrasound and vascular markers) were used. The signifficant differenece in the presence of an ultrasound and vascular markers between and ovary changes along with the signifficantly different level of Ca 125 is confirmed. To a specific marker certain score number was appointed and the scoring system was formed. The incidence of / ovary changes was observed in the researched group regarding anthropometric parameters (age, marital and menopausal status and number of deliveries). There is also signifficant difference in the incidence of / ovary tumor regarding these parameters. Based on combination of the scoring system and anthropometric parameters the decision rules for distinguishing from ovary tumors were formed. The logistic regression method was used. We proved that this method has higher accuracy in prediction of malignancy in women with ovary tumors than using morphological, doppler or anthropometric parameters separately. Introduction Ovarian cancer is the leading cause of mortality among gynecological cancers. Almost half (47%) women died from reproductive organs cancer had an ovary cancer 1. The incidence of ovarian cancer is 17 in 100 000 in Croatian population with 2 the incidence slightly higher in the northern Croatian islands 3. The disease is asymptomatic in earlier stages of disease. Two thirds of patients occur with already advanced disease. Epithelial ovarian tumors occur in 65 75% of all ovarian tumors, represent the most common types of all ovarian neoplasm 4 and occur more frequently in older postmenopausal women 5. Commonly used specific markers for ovarian cancer are: biochemical marker Ca 125, ultrasound markers (morphology of the ovaries) and vascular markers, with more or less success. Ca 125 has a high sensitivity, but low specificity and its value in early detection of epithelial ovarian cancer is limited 17. Morphological markers are based on the»real-time«ultrasound, detect altered ovarian morphology. Most common scan protocols used for scoring systems or indexes include morphological changes associated with ovarian volume, its surface, the presence of papillae, the appearance of the complex cysts, fragmentation, thickness of the wall of the cyst, thickness of septa and echogenicity of the fluid 6 with large percentage of false positive results 7. Colored and pulsed Doppler can be used separately to distinct from lesions, but some authors believe that it does not reduce the percentage of false positive results 8. Our aim is to form the decision rules for distinguishing from lesions combining biochemical, morphological and vascular markers. Materials and Methods 201 women with ovarian tumor treated in»sestre milosrdnice«university Hospital Center participated in prospective study conducted during a period of three years. There were 120 patients (57.7%) with ovarian tumor and 81 patient (38.9%) with ovarian tumor. The parameters obtained during the preoperative preparation were: a basic history and the serum level of Received for publication June 25, 2011 775

CA 125 marker obtained using monoclonal antibodies (VITROS Immunodiagnostic Products CA 125 Reagent Pack II, Ortho Clinical Diagnostics). The cut off value for Ca125 in our laboratory was 21.0U/ml. Within 24 hours before te surgery every patient underwent transvaginal ultrasound, color and pulsed Doppler using ultrasound sonoline Antares Ultrasound Imaging System, Siemens, with a transvaginal transducer of 6.1 MHz. Parameters such as structure of the wall of the tumor, the existence of shadows or barriers, solid components and peritoneal fluid, changes in echogenicity and blood flow in tumor were detected. The blood flow was indirectly determined by measuring the resistance index RI (cut-off value to distinguish from change was RI 0.42). We used an ultrasound scoring system showed in Table 1, obtained by modifying the ultrasound scoring system described by Dr Kupe{i} 9. In every patient seven ultrasound parameters were studied. Certain number of points was assigned to every parameter (0 2). The final count of all obtained points presented the»score«. If the sum of changes (»score«) is less than 5 we presumed that TABLE 1 THE CRITERIA FOR DIAGNOSIS OF OVARIAN CANCER GAINED BY ULTRASOUND AND COLOR DOPPLER TEHNICQUE The wall structure Shadow Septa/ Bariers Solid components Echogenicity Peritoneal fluid Tumor Vascularisation Total <5 Points a) smooth or irregular 3mm 0 b) papillar growth >3mm 2 a) YES 0 b) NO 1 NO/thin 3mm 0 thick >3mm 1 0 0 <1cm 1 >1cm 2 translucent or diminished 0 mixed or high 2 No 0 Yes 1 RI>0.42 0 RI 0.42 2 5 the lesion is, and if the sum was equal or greater than 5 we presumed that the changes were more likely to be. Postoperatively, after the hystopatological analysis of the tumor we compared hystopatological findings with our preoperative evaluation of the tumor based on ultrasound scoring system and serum level of Ca 125. We investigated the association of marital status, age, parity and menopausal status with the incidence of ovarian cancer. Patients were divided in two groups: patients with and tumor. For comparation of these two groups, nonparametric Mann-Whitney test for numerical variables and c 2 for qualitative variables was used. Since the numerical variables did not show normal distribution nonparametric test was applied. For creation of the model, the logistic regression,stepping logistic regression with the method of inclusion and exclusion of variables is applied, as well as Quinlanov C5.0 algorithm. The models are presented in tables, and the C5.0 algorithm graphically in form of decision trees. Both models were validated with absolute predictive accuracy. The method of cross validation was applied. Results The age of the patients ranged from 16 to 82 years. Younger women were more likely to develop ovarian tumors. The mean age in that group was 45.4. years with standard deviation of 12.68 and median of 46 years. In the group with disease the mean age was 57.12 years with standard deviation 13:28 years and median of 55 years. The age difference between those two groups was statistically significant (p=0.001). The number of deliveries between two groups was also different with statistical significance (p=0.022). The level of serum marker CA 125 in patients with ovarian tumors was significantly lower than in the patients with ovary tumors (p=0.001, Table 2). In our study, sensitivity of CA125 marker was 85.19%, specificity 72.5%, the percentage of false positive results 32.35%, and the percentage of false negative results 12.12%. The score evaluation in patients with tumors and tumors resulted with similar observation (p=0.001, Table 2). Sensitivity of the score was 82.72%, specificity 89.2%, the percentage of false positives 16.25%, and false negatives 11:57%. Resistance in- 776 TABLE 2 SERUM MARKER CA125, SCORE AND RESISTANCE INDEX (RI) IN PATIENTS WITH BENIGN AND MALIGNANT OVARY TUMORS Benign tumors Malignant tumors p X* SD** Med*** X* SD** Med*** Ca 125 (U/ml) 24.79 37.59 12.47 748.11 1411.04 200 <0.001 Score 2.78 1.43 3 6.70 2.33 7 <0.001 RI 0.64 0.13 0.68 0.47 0.14 0.41 <0.001 * Mean, ** Standard deviation, *** Median

TABLE 3 THE DIFFERENCES BETWEEN BENIGN AND MALIGNANT OVARY TUMORS BEFORE AND AFTER MENOPAUSIS Postmenopausis Benign tumor Malignant tumor Yes 46 (38.3%) 56 (69.1%) No 74 (61.7%) 25 (30.9%) TABLE 5 CLASSIFICATION MATRIX OF THE LOGISTIC REGRESSION MODELS Estimated Estimated Sensitivity Really 116 4 96.67% Really 14 67 82.72% dex (RI) was also lower in patients with tumors compared to those with tumors (p=0.001, Table 2). Sensitivity of resistance index measurement was 53.1%, specificity 92.5%, percentage of false positives 17.3% and false negatives 25.5%. Analyzing the existence of menopause, 38.3% of patients with ovary tumor and 69.1% of patients with ovary disease were menopaused. The difference between the groups is statistically significant (p=0.001, Table 3). Predictive models for ovary cancer: six independent predictors (age, Ca 125, score, menopausal status, number of deliveries and marital status) and the final histological diagnosis for each patient (criterion variable) were used for logistic regression. The resulting model is shown in Table 4. The resulting model was statistically significant ( 2 log likelihood=101.3, c 2 =169.7, df=5, p<0.0001). The absolute model classification accuracy is 91.04%. The classification is shown in Table 5. Using Quinlan C5.0 algorithm multiple trials showed the decision tree to be the best stabile and acceptable model (Figure 1). The resulting model evaluation was performed using the cross validation process in 10 steps. An average classification error in the decision tree was 11.5% and the standard error vas 2.1%. Discussion The ovarian cancer is the subject of multiple studies. Weiss and colleagues 10 found higher occurrence of ovarian cancer (60 70%) in women who have never been married 40 years ago. Women with ovarian cancer are significantly younger, have higher levels of education, better incomes, fewer children and more likely that they are not married in comparison to women with diagnosed colorectal carcinoma 11. We observed the higher tendency for developing ovarian disease in unmarried group, and higher tendency for developing ovary disease in divorced women group. It is presumed that the amount of stress in the life of divorced women, has some connection with the development of disease, but unfortunately the overall number of divorced women in our study is 15. Due to the small sample of divorced women in our study, we cannot conduct valuable scientific conclusion regarding this observation but we conclude that it would be very interesting to continue the investigation in this direction. Most studies show that the risk for ovarian cancer decreases with the number of deliveries 2, with the explanation of longer anovulatory periods and reduced secretion of gonadotropins, which is considered to be a protective factor for ovarian cancer. The incidence of ovarian cancer in postmenopausis is significantly higher comparing to premenopausis 13, and is usually diagnosed in 5th, 6th and 7th decade of woman life 12. In our study, we observed distribution toward ovarian disease in the group of postmenopausal women, and toward ovarian changes in premenopausal women. The age of the patients is closely related to menopausal status. Our study showed statistically significant differences in the incidence of or ovarian changes regarding age with higher incidence of tumors in younger group and higher incidence of changes in older group. In the literature, the serum level of Ca 125 is most often mentioned marker for ovarian cancer. 83% of patients with epithelial ovarian cancer have Ca 125 serum level elevated. Ca 125 serum level is elevated in 50% of patients with the I stage of the dis- TABLE 4 THE RESULTS OF LOGISTIC REGRESSION 95% CI Variables B S.E. Wald df Sig Odds Ratio Lower Upper Years 0.033 0.031 1.15 1 0.283 1.033 0.97 1.10 Ca125 0.012 0.004 7.49 1 0.006 1.012 1.00 1.02 Score 0.883 0.169 27.27 1 0.000 2.419 1.74 3.37 Number of deliveries 0.221 0.207 1.14 1 0.286 1.248 0.83 1.87 Menopausis 0.206 0.728 0.08 1 0.777 1.229 0.29 5.12 Constant 7.25 1.502 23.27 1 0.000 777

SCORE >5 5 Ca 125 >134.9 134.9 SCORE 3 >3 Age >46 46 Ca 125 >39.66 39.66 Age >58 58 Fig. 1. The decision tree for prediction of / ovary changes. ease, 60% of patients in the II stage of the disease, and over 90% of patients with advanced stages of the disease. In this study, the serum level of CA 125 was significantly lower in the group with tumor in comparison to the patients with ovary tumor. For better accuracy in prediction of or tumors, some authors suggested combining ultrasonic parameters and the value of Ca 125 (13). Botsis and colleagues in the research on 62 women with ovarian masses showed significantly higher values of resistance index in ovarian changes comparing to ovarian tumors (14). Sensitivity of Doppler analysis was significantly higher compared to the Ca 125 serum level, but combining these two methods the sensitivity in prediction of pelvic masses increases. In accordance with the majority of statements from the literature, in our study, the value of resistance index (RI) was significantly lower in women with tumors in comparison to those with tumors. An ultrasound observed parameters for identification of or ovary tumors were: morphology of the masses with special reference to size changes, changes in echogenicity, presence of papillae, ascites, ovarian volume, thickness and regularity of the wall or other. Many authors formed a»scoring system«by associating to each parameter the number of points. Depending on the total score or change was predicted 6,9. The score which we describe in patients with disease is statistically more sensitive than the score in patients with form of the disease. Many authors in hope for the better success in distinguishing from ovary changes examined the concordance of individual reproductive, anthropometric, morphologic and color Doppler parameters obtained with the hystopatologic analysis, and tried to extract relevant parameters, with the attempt of creation more accurate model 15,16. We conclude that the multivariant logistic regression analysis for calculation of the probability for malignancy in the patient with adnexal mass is fairly accurate. Its accuracy in prediction of malignancy appears to be higher than prediction of malignancy using morphological, doppler or anthropometric parameters separately. REFERENCES 1. SCULLY RE, YOUNG RH, CLEMENT PB, Atlas of tumor pathology (Armed Forces of Pathology, Washington, DC, 1998). 2. ^ORU[I] A, Tumori jajnika i jajovoda. In: [IMUNI] V (Ed) Ginekologija (Naklada Ljevak, Zagreb, 2001). 3. RUDAN I, CAMPBELL H, RANZANI GN, STRNAD M, VORKO-JOVI] A, JOHN V, KERN J, IVANKOVI] D, STEVANOVI] R, VUCKOV S, VULETI] S, RIDAN P, Coll antropol, 23 (2) (1999) 547. 4. KOONINGS PP, CAMPBELL AC, MISHELL DR, GRI- MES DA, Obstet Gynecol, 74 (1989) 921. 5. SOLJA^I] VRANE[ H, KLARI] P, VRANE[ Z, GRUBI[I] G, GORAJ[^AN V, Coll antropol, 31 (2007) 541. 6. WANAPIRAK C, SRISUPUNDIT K, TONGSONG T, Asian Pacj Cancer Prev, 7 (3) (2006) 407. 7. TABOR A, JENSEN FR, BOCK JE, HOGDALL CK, J Med Screen, 1 (1994) 215. 8. EUROPEAN RANDOMISED TRIAL OF OVARIAN CANCER SCREENING PROTO- COL, (London, Wolfson Institute 1999) 9. KUPESIC S, BJELOS D, KURJAK A, Gynecol Perinatol, 9 (2000). 10. WEISS NS, YOUNG JL JR, ROTH GJ, J Natl Cancer Inst, 58 (4) (1977) 913. 11. ELTABBAKH 778

GH, NATARAJAN N, PIVER MS, METTLIN CJ, J Surg Oncol, 76 (4) (2001) 283. 12. CORRADO F, NOCCIOLI G, Minerva Ginecol, 46 (11) (1994) 601. 13. SMOLEN A, STACHOWICZ N, CZEKIEROWSKI A, KOTARSKI J, Ginekol Pol, 81 (4) (2010) 254. 14. BOTSIS D, KASSANOS D, KALOGIROU D, KARAKITOS P, LIAPIS A, ANTONIOU G, Maturitas, 26 (3) (1997) 203. 15. MERCE LT, CABALLERO RA, BARCO MJ, BAU S, LOPEZ G, Eur J Obstet Gynecol Reprod Biol, 76 (1) (1998) 97. 16. TAILOR A, JURKOVIC D, BOURNE TH, COLLINS WP, CAMPBELL S, Ultrasound Obstet Gynecol, 10 (1) (1997) 41. 17. GORI[EK MN, ORE[KOVI] S, BUT I, Coll Antropol, 35 (1) (2011) 223. H. Solja~i} Vrane{ University of Zagreb,»Sestre milosrdnice«university Hospital Center, Department of Gynecology and Obstetrics, Vinogradska 29, 10 000 Zagreb, Croatia e-mail: zoran.vranes@zg.htnet.hr PREDVIDLJIVOST ZLO]UDNOSTI RAKA JAJNIKA SA@ETAK Rak jajnika je po smrtnosti na vode}em mjestu me u ginekolo{kim karcinomima. Cilj ove studije bio je konstruirati pravila odlu~ivanja za razlikovanje ih od malignih promjena. Istra`ivanje je provedeno na uzorku od 201 `ene. Promatrani su naj~e{}e kori{teni ultrazvu~ni, vaskularni markeri i biokemijski marker Ca 125 za detekciju ovarijskog karcinoma. Potvr ene su statisti~ki zna~ajne razlike u pojavnosti markera ovisno o malignosti promjene kao i koncentracije Ca 125. Svakom markeru pridodan je odre eni broj koji u kona~nici formira sistem bodovanja. Tako er je pojavnost ih/malignih promjena promatrana obzirom na antropometrijske parametre (dob, bra~ni status, paritet, menopauza). Potvr ena je statisti~ki zna~ajno razli~ita pojavnost ih/malignih promjena obzirom na te parametre. Kombinacijom sistema bodovanja s antropometrijskim parametrima formirana su pravila odlu~ivanja za razlikovanje malignih od ih promjena jajnika. Kori{tena je metoda logisti~ke regresije za koju smo dokazali ve}u prediktivnost za maligne/e promjene jajnika od prediktivnosti koju daju navedeni paramtetri pojedina~no. 779